Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
GlobalRPh RX List - ZYVOX
Product / population
Linezolid - ZYVOX renal label; selected renal source sections only, not a complete prescribing monograph.
Renal method
Qualitative renal impairment; no numeric dose algorithm is inferred.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Label guidance versus selected expert dose reduction
The label does not require routine renal reduction. UCSF describes a selected strategy for stable patients with CrCl below 30 and an anticipated course longer than 10 days, after the initial 72 hours.
What to reconcile: Do not apply a reduced regimen universally. Retain the clinical-stability, duration, monitoring and specialist qualifiers.
Source difference identified; final patient-specific adjudication required.
Linezolid: qualified expert reduction versus label no-adjustment
UCSF describes an optional expert reduction for selected stable patients receiving a prolonged course, rather than a universal renal reduction. Its dialysis table remains separately stated.
What to reconcile: Document the source and qualifying clinical context; involve infectious diseases and consider drug-level monitoring. Do not apply the expert exception indiscriminately.
GlobalRPh-hosted RX List · Linezolid - ZYVOX renal label; selected renal source sections only, not a complete prescribing monograph.
Renal method: Qualitative renal impairment; no numeric dose algorithm is inferred. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Parent linezolid pharmacokinetics do not require renal dose adjustment, but inactive metabolites accumulate as renal function worsens; weigh the uncertain clinical significance against potential risks. The label directs administration after hemodialysis and reports approximately 30% removal in the described three-hour session. Peritoneal-dialysis pharmacokinetics are unavailable. This no-adjustment statement does not eliminate toxicity surveillance.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.